Journal: Journal of thrombosis and haemostasis : JTH

Article Title: Protective role of protein C inhibitor in monocrotaline-induced pulmonary hypertension.

doi: 10.1111/j.1538-7836.2006.02174.x

Figure Lengend Snippet: Fig. 5. Markers of coagulation and fibrinolysis system. Markers of coagulation and fibrinolysis systems were measured in bronchoalveolar lavage fluid using commercial enzyme immunoassay kits in wild-type mice treated with saline (WT/SAL, n ¼ 15) or monocrotaline (WT/MCT, n ¼ 13) and in protein C inhibitor transgenic mice treated with saline (TG/SAL, n ¼ 8) or monocrotaline (TG/MCT, n ¼ 11). (A) The level of thrombin– antithrombin complex was significantly different between WT/SAL and WT/MCT, between TG/SAL and TG/MCT, and between WT/MCT and TG/MCT mice. (B) The level of plasminogen activator inhibitor-1 was significantly different between WT/SAL and WT/MCT mice, and between TG/SAL and TG/MCT mice, but not between WT/MCT and TG/MCT mice or between WT/SAL and TG/SAL mice. (C) The level of tissue-type plasminogen activator was significantly different between WT/MCT and TG/MCT mice but not between WT/SAL and WT/MCT, TG/SAL and TG/MCT or WT/SAL and TG/SAL mice. Samples were tested in dupli- cate. Bars represent the means ± SEM. Statistical analysis was performed by ANOVA with Fisher’s predicted least significant difference test.

Article Snippet: The concentration of PCI-thrombin complex was measured by EIA using antithrombin antibody (Acris antibodies GmbH, Hiddenhausen, Germany) and biotin-labeled anti-PCI antibody.

Techniques: Coagulation, Enzyme-linked Immunosorbent Assay, Saline, Transgenic Assay

Journal: International Journal of Molecular Sciences

Article Title: Temporal Changes in Extracellular Vesicle Hemostatic Protein Composition Predict Favourable Left Ventricular Remodeling after Acute Myocardial Infarction

doi: 10.3390/ijms24010327

Figure Lengend Snippet: Temporal changes in LDL-EV hemostatic protein composition in post-AMI patients with adverse and reverse LV remodeling. Coagulation proteins (VWF, SerpinC1) and fibrinolytic protein (plasminogen) levels and their ratios (VWF:Plasminogen, SerpinC1:Plasmingen) in LDL-EVs of 198 post-AMI patients at baseline and after 1 and 6 month follow-up. ( A ) A diagram illustrating the studied hemostatic proteins in LDL-EVs. ( B – F ) Differences between baseline and follow-up measurements were established by Wilcoxon signed-ranked test (horizontal statistical bar). Differences in the three protein levels and the protein ratios between patients with adverse LV remodeling and reverse LV remodeling were established by Mann–Whitney U test (vertical statistical bar). Data are presented as mean ± SEM.

Article Snippet: The antibodies and recombinant proteins were as follows: for detection of VWF we used recombinant human VWF protein (Factor VIII free, Fitzgerald #30C-CP4003U, Fitzgerald Industries International, Acton, MA, USA), anti-human VWF (Fitzgerald #70R-10589, Fitzgerald Industries International, Acton, MA, USA), and biotinylated anti-human VWF (Fitzgerald #60R-1019, Fitzgerald Industries International, Acton, MA, USA); for detection of SerpinC1, anti-thrombin III antibody (NOVUS Biologicals #NBP1-05149, Littleton, CO, USA), human SerpinC1 biotinylated affinity purified antibody (R&D Systems #BAF1267, Minneapolis, MN, USA) and recombinant human SerpinC1 (R&D Systems #1267-PI-010, Minneapolis, MN, USA); for detection of plasminogen, anti-human plasminogen (NOVUS Biologicals NB120-10176, Littleton, CO, USA), biotinylated anti-human plasminogen (NOVUS Biologicals, NB120-10177, Littleton, CO, USA), and recombinant human plasminogen (R&D system,1939-SE-200, Minneapolis, MN, USA); and for detection of SerpinF2, anti-human SerpinF2 (R&D Systems #MAB1470, Minneapolis, MN, USA), biotinylated anti-human SerpinF2 (R&D Systems #BAF1470, Minneapolis, MN, USA) and recombinant human SerpinF2 (R&D Systems #1470-PI-010, Minneapolis, MN, USA).

Techniques: Coagulation, MANN-WHITNEY

Journal: International Journal of Molecular Sciences

Article Title: Temporal Changes in Extracellular Vesicle Hemostatic Protein Composition Predict Favourable Left Ventricular Remodeling after Acute Myocardial Infarction

doi: 10.3390/ijms24010327

Figure Lengend Snippet: ML-SEM modeling for LDL-EV proteins.

Article Snippet: The antibodies and recombinant proteins were as follows: for detection of VWF we used recombinant human VWF protein (Factor VIII free, Fitzgerald #30C-CP4003U, Fitzgerald Industries International, Acton, MA, USA), anti-human VWF (Fitzgerald #70R-10589, Fitzgerald Industries International, Acton, MA, USA), and biotinylated anti-human VWF (Fitzgerald #60R-1019, Fitzgerald Industries International, Acton, MA, USA); for detection of SerpinC1, anti-thrombin III antibody (NOVUS Biologicals #NBP1-05149, Littleton, CO, USA), human SerpinC1 biotinylated affinity purified antibody (R&D Systems #BAF1267, Minneapolis, MN, USA) and recombinant human SerpinC1 (R&D Systems #1267-PI-010, Minneapolis, MN, USA); for detection of plasminogen, anti-human plasminogen (NOVUS Biologicals NB120-10176, Littleton, CO, USA), biotinylated anti-human plasminogen (NOVUS Biologicals, NB120-10177, Littleton, CO, USA), and recombinant human plasminogen (R&D system,1939-SE-200, Minneapolis, MN, USA); and for detection of SerpinF2, anti-human SerpinF2 (R&D Systems #MAB1470, Minneapolis, MN, USA), biotinylated anti-human SerpinF2 (R&D Systems #BAF1470, Minneapolis, MN, USA) and recombinant human SerpinF2 (R&D Systems #1470-PI-010, Minneapolis, MN, USA).

Techniques: Coagulation

Journal: International Journal of Molecular Sciences

Article Title: Temporal Changes in Extracellular Vesicle Hemostatic Protein Composition Predict Favourable Left Ventricular Remodeling after Acute Myocardial Infarction

doi: 10.3390/ijms24010327

Figure Lengend Snippet: Area under the receiver-operating curve (AUC) of different candidate markers predicting reverse LV remodeling.

Article Snippet: The antibodies and recombinant proteins were as follows: for detection of VWF we used recombinant human VWF protein (Factor VIII free, Fitzgerald #30C-CP4003U, Fitzgerald Industries International, Acton, MA, USA), anti-human VWF (Fitzgerald #70R-10589, Fitzgerald Industries International, Acton, MA, USA), and biotinylated anti-human VWF (Fitzgerald #60R-1019, Fitzgerald Industries International, Acton, MA, USA); for detection of SerpinC1, anti-thrombin III antibody (NOVUS Biologicals #NBP1-05149, Littleton, CO, USA), human SerpinC1 biotinylated affinity purified antibody (R&D Systems #BAF1267, Minneapolis, MN, USA) and recombinant human SerpinC1 (R&D Systems #1267-PI-010, Minneapolis, MN, USA); for detection of plasminogen, anti-human plasminogen (NOVUS Biologicals NB120-10176, Littleton, CO, USA), biotinylated anti-human plasminogen (NOVUS Biologicals, NB120-10177, Littleton, CO, USA), and recombinant human plasminogen (R&D system,1939-SE-200, Minneapolis, MN, USA); and for detection of SerpinF2, anti-human SerpinF2 (R&D Systems #MAB1470, Minneapolis, MN, USA), biotinylated anti-human SerpinF2 (R&D Systems #BAF1470, Minneapolis, MN, USA) and recombinant human SerpinF2 (R&D Systems #1470-PI-010, Minneapolis, MN, USA).

Techniques: